Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XE3D | ISIN: IE00BJMZDW83 | Ticker-Symbol: DHG
Frankfurt
14.11.24
08:07 Uhr
4,425 Euro
-0,060
-1,34 %
Branche
Hotels/Tourismus
Aktienmarkt
ISEQ-20
1-Jahres-Chart
DALATA HOTEL GROUP PLC Chart 1 Jahr
5-Tage-Chart
DALATA HOTEL GROUP PLC 5-Tage-Chart
RealtimeGeldBriefZeit
4,4204,50510:09
Dow Jones News
188 Leser
Artikel bewerten:
(1)

Dalata Hotel Group PLC: HOL-Holding(s) in Company

Finanznachrichten News

DJ Dalata Hotel Group PLC: HOL-Holding(s) in Company*

Dalata Hotel Group PLC (DAL,DHG) 
Dalata Hotel Group PLC: HOL-Holding(s) in Company* 
30-Oct-2024 / 08:12 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
Standard Form TR-1 
Standard form for notification of major holdings 
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the Central Bank of Ireland)i 
 
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: 
Dalata Hotel Group PLC (Ticker: DHG ID, ISIN: IE00BJMZDW83  ) 
2. Reason for the notification (please tick the appropriate box or boxes): 
[X] An acquisition or disposal of voting rights 
[ ] An acquisition or disposal of financial instruments 
[ ] An event changing the breakdown of voting rights 
[ ] Other (please specify)iii: 
 
3. Details of person subject to the notification obligationiv: 
                        City and country of registered office (if applicable): 
Name: TimesSquare Capital Management, LLC 
                        New York City, NY. United States 
4. Full name of shareholder(s) (if different from 3.)v: 
TimesSquare Capital Management, LLC on behalf of its advisory clients. 
5. Date on which the threshold was crossed or reachedvi:10/28/2024 
 
6. Date on which issuer notified: 10/29/2024 
 
7. Threshold(s) that is/are crossed or reached: Below 3% 
 
8. Total positions of person(s) subject to the notification obligation: 
                               % of voting rights 
                  % of voting rights    through financial   Total of both Total number of 
                  attached to shares (total instruments      in % (9.A +  voting rights of 
                  of 9.A)          (total of 9.B.1 +   9.B)      issuervii 
                               9.B.2) 
Resulting situation on the date on 
which threshold was crossed or 
reached 
Position of previous notification Not applicable 
(if applicable) 
 
9. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii: 
A: Voting rights attached to shares 
            Number of voting rightsix    % of voting rights 
Class/type of 
shares 
ISIN code (if     Direct      Indirect    Direct            Indirect 
possible) 
 
Ordinary shares, 
                    Not applicable                Not applicable 
IE00BJMZDW83 
 
 
SUBTOTAL A 
 
B 1: Financial Instruments according to Regulation 17(1)(a) of the Regulations 
Type of financial    Expiration Exercise/     Number of voting rights that may be acquired 
instrument        datex   Conversion Period if the instrument is exercised/converted.  % of voting rights 
                  xi 
Not applicable 
 
 
                  SUBTOTAL B.1    Not applicable 
 
B 2: Financial Instruments with similar economic effect according to Regulation 17(1)(b) of the Regulations 
Type of financial   Expiration  Exercise/ Physical or cash                     % of voting 
instrument       datex    Conversion settlementxii     Number of voting rights      rights 
                  Period xi 
Not applicable 
 
 
                        SUBTOTAL B.2      Not applicable 
 
10. Information in relation to the person subject to the notification obligation (please tick the applicable box): 
 
[X] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not 
control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.xiii 
 
[ ] Full chain of controlled undertakings through which the voting rights and/or the 
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv: 
 
       % of voting rights if it equals % of voting rights through financial    Total of both if it equals or 
Namexv    or is higher than the notifiable instruments if it equals or is higher than is higher than the notifiable 
       threshold            the notifiable threshold          threshold 
 
 
 
 
 
 
11. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date] 
Not applicable. 
 
12. Additional informationxvi: 
TimesSquare Capital Management, LLC ("TimeSquare") is registered investment adviser under the Investment Advisers Act 
of 1940, as amended and is regulated by the Securities and Exchange Commission in the United States. In the normal 
course of TimesSquare business it will acquire and dispose of equity securities on behalf of its clients. Part of 
TimesSquare's contractual obligations for its clients is to exercise proxy voting authority on the securities it 
acquires and disposes of. 

Done at New York, NY, United States of America on 29 October 2024.

Annex: Notification of major holdings (only to be filed with the Central Bank of Ireland and not with the relevant 
issuer) 
A: Identity of the person subject to the notification obligation 
Full name (including legal form for legal entities) 
TimesSquare Capital Management, LLC 
Contact address (registered office for legal entities) 
75 Rockefeller Plaza, 30th Floor, New York, NY 10019 
E-Mail 
Compliance@tscmllc.com 
Phone number / Fax number 
917-342-7958 
Other useful information (at least legal a contact person for legal persons) 
 
B: Identity of the notifier, if applicable 
Full name 
Joseph McComb, Chief Operating Officer of TimesSquare 
Contact address 
75 Rockefeller Plaza, 30th Floor, New York, NY 10019 
E-Mail 
Joseph.mccomb@tscmllc.com 
Phone number / Fax number 
917-342-7800 
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification 
obligation) 
 
 
C: Additional information: 
 
 

The Central Bank of Ireland ("Central Bank") may process personal data provided by you in order to fulfil its statutory functions or to facilitate its business operations. Any personal data will be processed in accordance with the requirements of data protection legislation. Any queries concerning the processing of personal data by the Central Bank may be directed to dataprotection@centralbank.ie. A copy of the Central Bank's Data Protection Notice is available at www.centralbank.ie/fns/privacy-statement.

Notes

i. Persons completing this form should have regard to the requirements of the Transparency (Directive 2004/109/EC) Regulations 2007 as amended (the "Regulations"), the Central Bank of Ireland's Transparency Rules (the "Transparency Rules") and Commission Delegated Regulation (EU) 2015/761 of 17 December 2014.

ii Full name of the legal entity and other identifying specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity).

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC); or (c) the holder of financial instruments referred to in Regulation 17(1) of the Regulations (Article 13(1) of Directive 2004/109/EC).

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

In relation to the transactions referred to in points (b) to (h) of Regulation 15 of the Regulations (Article 10 of Directive 2004/109/EC), the following list is provided as an indication of the persons who should be mentioned:

- in the circumstances foreseen in letter (b) of Regulation 15 of the Regulations (Article 10 of Directive 2004/109 /EC), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

- in the circumstances foreseen in letter (c) of the Regulation 15 of the Regulations (Article 10 of Directive 2004/ 109/EC), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

- in the circumstances foreseen in letter (d) of Regulation 15 of the Regulations (Article 10 of Directive 2004/109 /EC), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

- in the circumstances foreseen in letter (e) of Regulation 15 of the Regulations (Article 10 of Directive 2004/109 /EC), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Regulation 14 of the Regulations (Article 9 of Directive 2004/109/EC), under letters (a) to (d) of Regulation 15 of the Regulations (Article 10 of Directive 2004/109/EC) or under a combination of any of those situations, the controlled undertaking;

- in the circumstances foreseen in letter (f) of Regulation 15 of the Regulations (Article 10 of Directive 2004/109 /EC), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

- in the circumstances foreseen in letter (g) of Regulation 15 of the Regulations (Article 10 of Directive 2004/109 /EC), the natural person or legal entity that controls the voting rights;

- in the circumstances foreseen in letter (h) of Regulation 15 of the Regulations (Article 10 of Directive 2004/109 /EC), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

v Applicable in the cases provided for in Regulation 15(b) to (h) of the Regulations (Article 10 (b) to (h) of Directive 2004/109/EC). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Regulation 15 of the Regulations (Article 10 Directive 2004/109/EC) unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with the requirements of the Regulations and the Transparency Rules.

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

vii The total number of voting rights shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

viii If the holding has fallen below the lowest applicable threshold in accordance with the Regulations and the Transparency Rules the holder is not obliged to disclose the extent of the holding only that the holding is "below 3%" or "below 5%" as appropriate.

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (Regulation 17(4) of the Regulations/Article 13(1a) of Directive 2004/109/EC).

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

xiv The full chain of controlled undertakings, starting with the ultimate controlling natural person or legal entity, has to be presented also in cases in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification, as only thus will the markets get a full picture of the group holdings. In the case of multiple chains through which the voting rights and/or financial instruments are effectively held, the chains have to be presented chain by chain leaving a row free between different chains (e.g.: A, B, C, free row, A, B, D, free row, A, E, F etc.).

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespective of whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

xvi Example: Correction of a previous notification.

----------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

ISIN:      IE00BJMZDW83, IE00BJMZDW83 
Category Code: HOL 
TIDM:      DAL,DHG 
LEI Code:    635400L2CWET7ONOBJ04 
OAM Categories: 2.3. Major shareholding notifications 
Sequence No.:  355977 
EQS News ID:  2018855 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2018855&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

October 30, 2024 04:12 ET (08:12 GMT)

© 2024 Dow Jones News
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.